Company Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.
The company’s lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or FcγR to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials.
Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 157 |
| CEO | Michel Detheux |
Contact Details
Address: 321 Arsenal Street, Suite 301 Watertown, Massachusetts 02472 United States | |
| Phone | 339 217 0161 |
| Website | iteostherapeutics.com |
Stock Details
| Ticker Symbol | ITOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001808865 |
| CUSIP Number | 46565G104 |
| ISIN Number | US46565G1040 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michel Detheux Ph.D. | President, Chief Executive Officer and Director |
| Matthew Gall | Chief Financial Officer |
| Matthew A. Call M.B.A. | Chief Operating Officer |
| Dr. Yvonne McGrath Ph.D. | Chief Scientific Officer |
| Adi Osovsky | Executive Vice President of Legal |
| Philippe Brantegem | Executive Vice President of Human Resources |
| Dr. David Feltquate M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 21, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 30, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |